FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
Notice of Trading Update
hVIVO plc has highlighted a major validation of its clinical capabilities after its client Cidara Therapeutics agreed to be acquired by pharmaceutical giant MSD in a deal worth approximately $9.2
hVIVO plc has announced that its German subsidiary, CRS, has landed more than £5 million in new contracts since September, driven in large part by two returning mid-sized German pharmaceutical
Join us for an insightful conversation on hMPV featuring our Chief Scientific Officer, Dr Andrew Catchpole and Guy Boivin, a professor from Laval University and one of the founding fathers
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
Positive data from multiple novel human challenge models hVIVO presentations made at influential ESWI and World Vaccine Congress Europe conferences
hVIVO to present at Jefferies Global Healthcare Conference
Interim results Trading in line with expectations for full year Returning to growth in 2026
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of